mRNA Drug and Vaccine Toxicity By Brian Simpson

Evidence seems to be slowly seeping into the mainstream now about the safety and toxicity issues associated with the Covid-19 vaccines. One recent article "Strategies to Reduce the Risks of mRNA Drug and Vaccine Toxicity" in the prestigious medical journal Nature Reviews Drug Discovery, admits that there are issues of toxicity with the Covid-19 mRNA vaccines, which the health authorities are still pushing for now reluctant Australians to have. The article states: "avoiding unacceptable toxicity with mRNA drugs and vaccines presents challenges. Lipid nanoparticle structural components, production methods, route of administration and proteins produced from complexed mRNAs all present toxicity concerns. Here, we discuss these concerns, specifically how cell tropism and tissue distribution of mRNA and lipid nanoparticles can lead to toxicity, and their possible reactogenicity." Translation: the mRNA vaccines have toxic effects, and we need to research measures to minimise this.

This is a far departure from the safe and effective narrative, with very rare side-effects that the Australian health authorities continue to push. At every point, Covid has been a great cover-up, and only now is the truth beginning to out.

https://www.trialsitenews.com/a/bombshell-ex-moderna-preclinical-scientists-acknowledge-serious-safety-concern-with-current-mrna-technology-e5f38e7f

"Implicitly raising considerable concern about the safety of current mRNA vaccines plus the growing therapeutics and vaccines clinical pipeline, the new review titled "Strategies to reduce the risks of mRNA drug and vaccine toxicity" while not expressing anything inherently new, raises the alarm as to the potential safety risks associated with this first generation of commercialized mRNA vaccines. The authors, deep experts in preclinical mRNA-related science, educate the reader concerning imminent challenges associated with "lipid nanoparticle structural components, production methods, route of administration and proteins produced from complexed mRNAs." All represent toxicity concerns that cannot be ignored anymore. How can one transcend these challenges thus making mRNA vaccines safer? Just like TrialSite emphasized all during the pandemic, the answer lies in the use of emerging capability based on the unfolding relevant science as well as more comprehensive holistic nonclinical stage drug development to de-risk this class of product. TrialSite chronicled how considerable segments of this nonclinical stage were avoided due to COVID-19 pandemic conditions and the need for speed. This media for example, identified Pfizer's lack of IND-enabled preclinical studies when reviewing documentation from the European Medicines Agency well back in 2021. Toxicological pathology informs potential human risk of adverse effects associated with exposure to mRNA drugs and vaccines. Present mRNA drugs and vaccines delivered in lipid nanoparticles (LNPs) and containing numerous buffer and small-molecule lipid components are all capable of inducing toxicities. The complexity inherent in these mRNA products combined with vaccine delivery formulation raises toxicity risk concerns. In the Nature Reviews Drug Discovery review paper, the authors seek to address important questions: What toxicities and pathogenicities are identified during the preclinical development of novel mRNA drugs and vaccines? How might these be linked to their components? What are some emerging toxicological concerns? What are important advances in next-generation, nonclinical models and how may such capability be leveraged to de-risk the preclinical development of novel mRNA formulations?

This admission concerning risks associated with the current mRNA vaccine products occurs here in plain sight—in the prestigious medical journal Nature Reviews Drug Discovery.

https://www.nature.com/articles/s41573-023-00859-3

mRNA formulated with lipid nanoparticles is a transformative technology that has enabled the rapid development and administration of billions of coronavirus disease 2019 (COVID-19) vaccine doses worldwide. However, avoiding unacceptable toxicity with mRNA drugs and vaccines presents challenges. Lipid nanoparticle structural components, production methods, route of administration and proteins produced from complexed mRNAs all present toxicity concerns. Here, we discuss these concerns, specifically how cell tropism and tissue distribution of mRNA and lipid nanoparticles can lead to toxicity, and their possible reactogenicity. We focus on adverse events from mRNA applications for protein replacement and gene editing therapies as well as vaccines, tracing common biochemical and cellular pathways. The potential and limitations of existing models and tools used to screen for on-target efficacy and de-risk off-target toxicity, including in vivo and next-generation in vitro models, are also discussed."